Key facts
- The U.S. has secured 26 deals with pharmaceutical companies to lower drug prices and encourage investment.
- These 'most-favored-nation' deals aim to match U.S. prices with those in Europe and secure U.S. manufacturing commitments.
- Pharmaceutical companies have pledged over $19.6 billion in new investments in the U.S.
- European industry leaders warn that these U.S. policies could lead to delayed drug launches and reduced patient access in Europe.
- Proposed European incentives, such as patent extensions, are considered by some to be insufficient and too late to retain industry investment.
The U.S. is intensifying pressure on pharmaceutical companies through 'most-favored-nation' deals, aiming to lower drug prices for American consumers and secure significant investment in the United States. President Donald Trump's administration has announced 26 such agreements, with companies pledging over $19.6 billion for new U.S. facilities.
These deals compel companies to launch new medicines in the U.S. at prices comparable to those in Europe, while also committing to investment. This strategy has raised concerns among European industry leaders and policymakers, who warn that it could lead to a diversion of investment and research away from Europe.
Adrian van den Hoven, director general of Medicines for Europe, stated that companies might hesitate to launch drugs in Europe if they anticipate lower prices compared to the U.S., potentially impacting patient access to new treatments. The inclusion of mid-sized and generic drugmakers in the latest round of deals signals an expansion of this policy.
While Europe is attempting to counter this trend with measures like a proposed patent extension for biotech drugs, some argue these efforts are insufficient and may come too late. Alexander Natz of EUCOPE noted that the proposed Biotech Act has too many conditions and will likely not take effect in time to prevent a pivot towards the U.S.
European officials, including a spokesperson for the European Commission, are closely monitoring the situation and its potential effects on the European market, emphasizing their priority of ensuring timely access to affordable medicines. However, some analyses suggest a decline in drug launch applications to the European Medicines Agency in early 2026.
Experts like Diederik Stadig highlight that Europe faces deeper structural issues, including a fragmented pricing model and a 'commercialization gap' where European scientific innovation often leads to market launches elsewhere. This, combined with the U.S. policy, creates significant pressure for Europe to reform its market conditions to remain competitive in the life sciences sector.